No Slow Start for TJC Enforcing Vaccine Requirements
Surveyors with TJC are looking at vaccination rates and will score a hospital if it is not 100% compliant in the states where the newest Conditions of Participation (CoPs) outlining vaccination expectations are already effective.
Quintuple Aim: Health Equity Added to Healthcare Improvement Directive
In 2008, the Triple Aim for healthcare improvement was introduced, featuring improvement of population health, enhancement of the care experience, and reduction of costs. In 2014, the Quadruple Aim for healthcare improvement was created with the addition of workforce well-being as a fourth element to address healthcare worker burnout.
OSHA Urges Action on Spike in Healthcare Injuries, Illnesses
There was a 38.3% increase across private industry cases in days away from work (DAFW) in 2020, the BLS reported in its Survey of Occupational Injuries and Illnesses (SOII), the bureau’s annual tally of nonfatal workplace injuries and illnesses. The BLS also compiles an annual Census of Fatal Occupational Injuries (CFOI).
Quality’s Impact on Sustainability and the Future
Chartered Quality Institute recently celebrated World Quality Week, which focuses on the quality management profession, concentrating on quality’s role in better sustainability as well as its environmental, social, and governance impact. In a healthcare landscape that is growing ever more complex, quality’s impact on sustainability and how the industry reacts and responds to changing regulations is more important than ever.
A Collaborative Effort to Improve Antimicrobial Stewardship and Beyond
Pharmacies need a streamlined clinical and operational option to integrate data and deliver actionable analytics in one place rather than across disparate sources. This is particularly important in infection prevention and antimicrobial stewardship programs, where providers need to identify indications, treatment options, resistance considerations, potential drug interactions, and pharmacology.
The Top Three Things Healthcare Executives Should Prioritize in 2022
Finding the right business model to support the clinical mission among these challenges is critical but highly challenging. Enhanced use of data and data analytics, however, can help address these challenges both short and long term. Here are the three things healthcare executives should prioritize in 2022.
Boosting Value From Genomic Database Participation
To boost the promise of more effective therapies, a number of organizations are working to capture the patient data that will drive research around precision medicine, with the National Institutes of Health’s All of Us research program being a notable example. Now, Seven Bridges Genomics, a bioinformatics ecosystem provider, has announced the formation of the Unified Patient Network (UPN).
Boosting Quality, Patient Adherence While Cutting Costs with Medication Management Devices
Medication non-adherence, particularly among senior patients, is a costly problem facing the American healthcare system. This issue results in an estimated $100 billion–$290 billion in annual costs, according to studies reviewed in the Annals of Internal Medicine (AIM). Other research cited by AIM indicates that 20%–30% of prescribed medications go unfilled by patients and approximately 50% of medications for chronic diseases aren’t used by patients as prescribed.
Why Hybrid Trials May Be the Best Choice for Patient Centricity
Engaging with patients early in the study design process allows sponsors to better understand what would make a trial work best for patients, their caregivers, and their families. To get to that point, patient groups can help sponsors to identify barriers up front such as travel distance, length of study visits, and financial costs to patients to determine what aspects of the trial could be better designed to reduce patient burden.
Antibiotics Market ‘Fragile and Failing,’ Report Says
There is an ongoing struggle between antibiotic resistant infections—superbugs such as Methicillin-resistant Staphylococcus aureus—and the makers of antibiotics. The global death toll is alarming, with more than 1.2 million people dying annually, and estimated mortality expected to reach 10 million people annually by 2050.